HOOK - HOOKIPA Pharma Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.06
-1.74 (-12.61%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close13.80
Open14.01
Bid12.06 x 1400
Ask12.90 x 1100
Day's Range12.01 - 14.37
52 Week Range6.06 - 14.76
Volume140,292
Avg. Volume105,303
Market Cap306.427M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.96
Earnings DateNov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.60
  • Is HOOKIPA Pharma (NASDAQ:HOOK) Using Debt In A Risky Way?
    Simply Wall St.

    Is HOOKIPA Pharma (NASDAQ:HOOK) Using Debt In A Risky Way?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • GlobeNewswire

    HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entry

    NEW YORK and VIENNA, Austria, Jan. 06, 2020 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • GlobeNewswire

    HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-201 for the Treatment of Human Papillomavirus 16-Positive Cancers

    HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that the first patient has been dosed in a Phase 1/2 clinical trial (NCT04180215) of HB-201, an immunotherapy for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers. This trial is HOOKIPA’s first clinical trial in immuno-oncology. In addition to strong immunogenicity, HOOKIPA observed robust anti-tumor activity in mouse models.

  • Hedge Funds Have Never Been This Bullish On HOOKIPA Pharma Inc. (HOOK)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On HOOKIPA Pharma Inc. (HOOK)

    Is HOOKIPA Pharma Inc. (NASDAQ:HOOK) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

  • GlobeNewswire

    HOOKIPA Pharma to Present at Piper Jaffray 31st Annual Healthcare Conference

    NEW YORK and VIENNA, Austria, Nov. 25, 2019 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • GlobeNewswire

    HOOKIPA Pharma Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

    NEW YORK and VIENNA, Austria, Nov. 12, 2019 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • GlobeNewswire

    HOOKIPA Pharma To Report Third Quarter 2019 Financial Results on November 12, 2019

    NEW YORK and VIENNA, Austria, Nov. 04, 2019 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • GlobeNewswire

    HOOKIPA Pharma to Present at Upcoming Conferences in November

    NEW YORK and VIENNA, Austria, Oct. 31, 2019 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • GlobeNewswire

    HOOKIPA Announces Key Hires to its Executive Team

    HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that Christine D. Baker has joined HOOKIPA as Chief Business Officer (CBO) and Roman Necina, PhD, will join as Chief Technology Officer (CTO) in November. Following the start of a Phase 2 Cytomegalovirus vaccine trial, the IND clearance for its first immuno-oncology trial in HPV+ cancers, a collaboration agreement with Gilead for HBV and HIV therapeutics, and the completion of its initial public offering in April 2019, HOOKIPA is starting the next phase of its strategic development.

  • GlobeNewswire

    HOOKIPA to Present Data Demonstrating the Potential of its TheraT® Technology at the Upcoming CICON Conference in Paris

    NEW YORK and VIENNA, Austria, Sept. 19, 2019 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • GlobeNewswire

    HOOKIPA Pharma to Present at Upcoming Investor Conferences in September

    NEW YORK and VIENNA, Austria, Aug. 29, 2019 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • GlobeNewswire

    HOOKIPA Pharma Reports Second Quarter 2019 Financial Results and Clinical Progress Highlights

    NEW YORK and VIENNA, Austria, Aug. 12, 2019 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics, targeting infectious.

  • What Kind Of Shareholders Own HOOKIPA Pharma Inc. (NASDAQ:HOOK)?
    Simply Wall St.

    What Kind Of Shareholders Own HOOKIPA Pharma Inc. (NASDAQ:HOOK)?

    A look at the shareholders of HOOKIPA Pharma Inc. (NASDAQ:HOOK) can tell us which group is most powerful. Institutions...

  • Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
    Zacks

    Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study

    Key highlights of the past week include collaborations and other pipeline updates.

  • Dow Jones Futures: Illumina, Profitable Marijuana Stock Tumble; Amgen-Novartis Alzheimer's Drug Fails
    Investor's Business Daily

    Dow Jones Futures: Illumina, Profitable Marijuana Stock Tumble; Amgen-Novartis Alzheimer's Drug Fails

    Dow Jones futures: Illumina stock and profitable marijuana stock Innovative Industrial Properties fell late on news. An Amgen-Novartis Alzheimer's drug failed. Hookipa Pharma soared.

  • Benzinga

    The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on July 11) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) GALAPAGOS ...

  • GlobeNewswire

    HOOKIPA Announces FDA Clearance of IND Application for HB-201 Clinical Trial to Treat HPV-Positive Cancers

    HOOKIPA Pharma Inc. (HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that its Investigational New Drug (IND) Application for a Phase 1/2 clinical trial of HB-201, a TheraT®*-based immunotherapy, for the treatment of Human Papilloma Virus (HPV)-positive cancers is now effective following the clearance by the U.S. Food and Drug Administration (FDA). HB-201 (LCMV) is a TheraT®-based product candidate expressing a non-oncogenic but highly antigenic E6/E7 fusion protein derived from HPV16. HOOKIPA will now start a clinical trial with the goal to provide therapeutic benefit to patients with HPV16+ cancers.

  • TheStreet.com

    [video]Hookipa Soars on FDA OK of Early Stage Trial For Cancer Treatment

    Shares of Hookipa Pharma Inc. surged in after-hours trading Thursday after the company said the FDA approved an early stage trial of its treatment for human papilloma virus (HPV)-positive cancers. The company said in a statement that it intends to start the phase 1/2 clinical trial of its TheraT immunotherapy in the second half of 2019 with preliminary safety and efficacy data expected in late 2020 or early 2021. Human papilloma virus is estimated to cause about 5% of the worldwide burden of cancer including approximately 99% of cervical cancers, 25% to 60% of head and neck cancers, 70% of vaginal cancers and 88% of anal cancers, the company said.

  • CNW Group

    CEO of Agrios Global Holdings Ltd. Presenting at The Advantage Strategy and Financial Conference June 14, 2019, in Vienna, Austria

    VANCOUVER , June 10, 2019 /CNW/ - Agrios Global Holdings Ltd. (AGRO.CN) (OTCQB: AGGHF) (FSE: ØSA - WKN-A2N62K) ("Agrios" or the "Company") is pleased to announce that Chris Kennedy , President & CEO of Agrios will be presenting at the Advantage Strategy and Financial Conference (ASFC) on Friday June 14, 2019 , in Vienna, Austria . The conference showcases international companies with innovations in technology in many sectors including agri-tech, biotech and medical/pharmaceutical applications and products. Agrios is one of several presenters recognized for their development of ground-breaking technologies and products in the areas of agri-tech applications and data analytics that have been invited to present at the conference.

  • GlobeNewswire

    HOOKIPA Pharma Reports First Quarter 2019 Financial Results and Recent Business Highlights

    HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reported recent business highlights and financial results for the first quarter ended March 31, 2019. “HOOKIPA’s achievements since the start of 2019 have demonstrated our ability to execute and deliver on key company goals. Also, we now have the financial strength to achieve major milestones on our journey to translate great science into clinical programs.

  • GlobeNewswire

    HOOKIPA Achieves Research Milestone in HBV Collaboration and License Agreement with Gilead

    HOOKIPA Pharma Inc. (HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has achieved a further research milestone in its collaboration and license agreement with Gilead Sciences, Inc. (“Gilead”) for development of a therapeutic hepatitis B virus (HBV) vaccine. Based on the terms of the agreement, HOOKIPA is entitled to a milestone payment from Gilead. HOOKIPA has completed the research milestone for HBV by designing and delivering 10 research-grade vectors to Gilead, along with the characterization of these vectors and delivery of a data package for the HBV program.

  • GlobeNewswire

    HOOKIPA Appoints David R. Kaufman to its Board of Directors

    HOOKIPA Pharma Inc. (HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of David R. Kaufman, M.D., Ph.D., to its Board of Directors. Prior to joining the Institute, he held several leadership positions at Merck Research Laboratories, including Head of Translational Oncology, Executive Director in Clinical Oncology and Associate Director of the Merck Drug Development and Leadership Program. Dr. Kaufman is a member of the Board of Directors of the Society for Immunotherapy of Cancer (SITC), a not-for-profit medical professional society dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.